10x Genomics [TXG] vs Veeva Systems [VEEV] Detailed Stock Comparison

10x Genomics

NASDAQ
Loading...

Veeva Systems

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: 10x Genomics wins in 6 metrics, Veeva Systems wins in 12 metrics, with 0 ties. Veeva Systems appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric10x GenomicsVeeva SystemsBetter
P/E Ratio (TTM)-8.5560.8410x Genomics
Price-to-Book Ratio2.057.3110x Genomics
Debt-to-Equity Ratio11.221.29Veeva Systems
PEG Ratio0.053.7910x Genomics
EV/EBITDA-11.0748.5710x Genomics
Profit Margin (TTM)-13.13%27.29%Veeva Systems
Operating Margin (TTM)-2.63%28.71%Veeva Systems
EBITDA Margin (TTM)N/A28.71%N/A
Return on Equity-11.30%13.70%Veeva Systems
Return on Assets (TTM)-9.45%7.24%Veeva Systems
Free Cash Flow (TTM)$-6.73M$1.09BVeeva Systems
1-Year Return-28.66%44.91%Veeva Systems
Price-to-Sales Ratio (TTM)2.4616.3610x Genomics
Enterprise Value$1.23B$42.24BVeeva Systems
EV/Revenue Ratio1.9014.2310x Genomics
Gross Profit Margin (TTM)72.34%75.26%Veeva Systems
Revenue per Share (TTM)$5$18Veeva Systems
Earnings per Share (Diluted)$-0.70$4.87Veeva Systems
Beta (Stock Volatility)2.050.98Veeva Systems
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

10x Genomics vs Veeva Systems Stock Performance Analysis

Loading Price Chart...

10x Genomics
Veeva Systems
10x Genomics Stock Overview | Veeva Systems Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
10x Genomics-8.23%-0.77%-16.73%-2.68%53.03%-18.25%
Veeva Systems2.16%2.79%8.29%8.98%42.60%45.42%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
10x Genomics-28.66%-54.65%-92.91%-77.81%-77.81%-77.81%
Veeva Systems44.91%102.66%-0.02%1,081.86%589.84%589.84%

News Based Sentiment: 10x Genomics vs Veeva Systems

10x Genomics

News based Sentiment: MIXED

October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.

View 10x Genomics News Sentiment Analysis

Veeva Systems

News based Sentiment: MIXED

October presented a mixed picture for Veeva, with strong financial results and growing industry adoption offset by notable insider selling and a rating downgrade. The upcoming Investor Day will be critical for clarifying the company's strategy and addressing investor concerns, making this a significant month for the investment story.

View Veeva Systems News Sentiment Analysis

Performance & Financial Health Analysis: 10x Genomics vs Veeva Systems

MetricTXGVEEV
Market Information
Market Cap i$1.59B$48.56B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i2,746,6601,277,350
90 Day Avg. Volume i2,469,4201,488,867
Last Close$11.60$306.22
52 Week Range$6.78 - $20.92$200.30 - $310.50
% from 52W High-44.55%-1.38%
All-Time High$208.99 (Jun 28, 2021)$343.96 (Aug 02, 2021)
% from All-Time High-94.45%-10.97%
Growth Metrics
Quarterly Revenue Growth0.13%0.17%
Quarterly Earnings Growth0.13%0.17%
Financial Health
Profit Margin (TTM) i-0.13%0.27%
Operating Margin (TTM) i-0.03%0.29%
Return on Equity (TTM) i-0.11%0.14%
Debt to Equity (MRQ) i11.221.29
Cash & Liquidity
Book Value per Share (MRQ)$6.21$40.51
Cash per Share (MRQ)$3.59$39.07
Operating Cash Flow (TTM) i$66.95M$1.35B
Levered Free Cash Flow (TTM) i$58.22M$1.10B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: 10x Genomics vs Veeva Systems

MetricTXGVEEV
Price Ratios
P/E Ratio (TTM) i-8.5560.84
Forward P/E i-10.4543.83
PEG Ratio i0.053.79
Price to Sales (TTM) i2.4616.36
Price to Book (MRQ) i2.057.31
Market Capitalization
Market Capitalization i$1.59B$48.56B
Enterprise Value i$1.23B$42.24B
Enterprise Value Metrics
Enterprise to Revenue i1.9014.23
Enterprise to EBITDA i-11.0748.57
Risk & Other Metrics
Beta i2.050.98
Book Value per Share (MRQ) i$6.21$40.51

Financial Statements Comparison: 10x Genomics vs Veeva Systems

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TXGVEEV
Revenue/Sales i$154.88M$759.04M
Cost of Goods Sold i$49.44M$173.82M
Gross Profit i$105.45M$585.22M
Research & Development i$64.25M$184.03M
Operating Income (EBIT) i$-48.53M$233.73M
EBITDA i$-32.89M$243.55M
Pre-Tax Income i$-33.51M$298.82M
Income Tax i$852,000$70.63M
Net Income (Profit) i$-34.36M$228.19M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TXGVEEV
Cash & Equivalents i$377.06M$1.96B
Total Current Assets i$579.73M$6.71B
Total Current Liabilities i$107.90M$1.46B
Long-Term Debt i$70.63M$66.57M
Total Shareholders Equity i$706.90M$6.21B
Retained Earnings i$-1.50B$3.68B
Property, Plant & Equipment i$55.58M$122.23M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TXGVEEV
Operating Cash Flow i$35.44M$810.54M
Capital Expenditures i$-1.89MN/A
Free Cash Flow i$32.46M$877.16M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTXGVEEV
Shares Short i17.35M5.41M
Short Ratio i7.583.60
Short % of Float i0.22%0.04%
Average Daily Volume (10 Day) i2,746,6601,277,350
Average Daily Volume (90 Day) i2,469,4201,488,867
Shares Outstanding i122.29M162.58M
Float Shares i109.33M150.41M
% Held by Insiders i0.02%0.09%
% Held by Institutions i1.05%0.89%

Dividend Analysis & Yield Comparison: 10x Genomics vs Veeva Systems

MetricTXGVEEV
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A